Skip to main content
生物谷 logo

生物谷 — Investor Relations & Filings

Ticker · 920266 Beijing Stock Exchange Manufacturing
Open in API
Filings indexed 570 across all filing types
Latest filing 2022-07-19 Regulatory Filings
Country CN China
Listing Beijing Stock Exchange 920266

About 生物谷

https://www.bioon.com/

Bio-Valley specializes in the research, development, and manufacturing of botanical-based therapeutic solutions, with a primary focus on cardiovascular and cerebrovascular health. The company is a leader in the industrialization of Erigeron breviscapus (Dengzhanhua), a botanical resource used for treating ischemic stroke and its sequelae. Its core product portfolio includes Dengzhan Shengmai Capsules and Dengzhan Xixin Injection, which are utilized in clinical settings for their neuroprotective and microcirculation-improving properties. Bio-Valley maintains a comprehensive value chain encompassing botanical cultivation, standardized extraction, and large-scale production. By leveraging advanced extraction technologies and rigorous quality control, the company provides evidence-based solutions for chronic disease management and geriatric care.

Recent filings

Filing Released Lang Actions
关于变更股东大会见证律师事务所的公告
Regulatory Filings Classification · 95% confidence The document is an announcement regarding the change of the law firm witnessing the shareholder meeting for the company. It does not contain financial data, audit information, or detailed report content. It is a regulatory announcement about a procedural change related to the shareholder meeting. The document is short (741 characters) and serves as a formal notification rather than a report or detailed filing. Therefore, it fits best under Regulatory Filings (RNS).
2022-07-19 Chinese
股权司法冻结的公告(更正公告)
Regulatory Filings Classification · 95% confidence The document is a public announcement by the company regarding a correction to a previous announcement about judicial freezing of shares involving the controlling shareholders. It includes details about the shareholding and freezing status, and clarifies errors in a prior announcement. The document is short (1241 characters) and is a correction notice rather than a financial report or detailed filing. It does not contain financial statements, management discussion, or regulatory certifications. It is an announcement related to shareholding status and legal restrictions on shares, but not a major shareholding notification (MRQ) since it focuses on judicial freezing and correction of a prior announcement. The best fitting category is Regulatory Filings (RNS), which covers miscellaneous regulatory announcements and corrections that do not fit other specific categories.
2022-07-18 Chinese
股权司法冻结的公告（更正后）
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the judicial freezing of shares held by major shareholders and the actual controller of the company. It details the number of shares frozen, the legal basis for the freezing, the impact on the company, and related court documents. There is no financial data, no discussion of financial results, no management commentary on earnings, no presentation materials, and no mention of report publication. The document is a regulatory announcement about a legal event affecting share ownership and control risks. This fits best under Regulatory Filings (RNS) as it is a general regulatory announcement about a significant legal and ownership matter that does not fit other specific categories like Major Shareholding Notification (MRQ) because it concerns judicial freezing rather than share ownership changes due to transactions. The document length is 2513 characters, which is short and typical for an announcement rather than a full report. Therefore, the classification is RNS with high confidence.
2022-07-18 Chinese
第四届董事会第七次会议决议公告
Board/Management Information Classification · 95% confidence The document is a formal announcement of the resolutions passed at the seventh meeting of the fourth board of directors of Yunnan Biological Valley Pharmaceutical Co., Ltd. It details the meeting's attendance, agenda, voting results, and related opinions. The content focuses on board decisions, including a proposal to initiate civil litigation against the controlling shareholder and actual controller for misappropriation of company funds. There is no financial data, earnings information, or report publication mentioned. The document is clearly about board meeting resolutions and management decisions, fitting the category of Board/Management Information (MANG). The document length is short (1519 characters), and it is not an announcement of a report publication but a substantive board meeting resolution announcement.
2022-07-17 Chinese
华融证券关于生物谷股东金沙江及林艳和所持公司股份被司法冻结的核查意见
Regulatory Filings Classification · 95% confidence The document is a detailed legal and regulatory disclosure regarding the judicial freezing of shares held by specific shareholders of a company. It includes specifics about the number of shares frozen, the reasons for freezing, related legal documents, and the impact on company control and operations. It references regulatory bodies such as the China Securities Regulatory Commission and Beijing Stock Exchange disciplinary actions. The document is not a financial report, earnings release, or management discussion but rather a regulatory compliance and legal status update. It does not fit into categories like Annual Report, Interim Report, or Earnings Release. It is a regulatory announcement about legal and compliance matters related to share freezing and investigations. Therefore, the most appropriate classification is Regulatory Filings (RNS). The document length (6956 characters) and content confirm it is a substantive regulatory filing rather than a brief announcement or certification.
2022-07-17 Chinese
详式权益变动财务顾问核查意见
Major Shareholding Notification Classification · 95% confidence The document is a detailed financial advisor's verification opinion on a "详式权益变动报告书(修订稿)" which translates to a "Detailed Equity Change Report (Revised)" related to a significant equity transaction involving a listed company (云南生物谷药业股份有限公司). The document references relevant Chinese securities laws and regulations, including the Securities Law, the Administrative Measures for Takeovers, and specific disclosure standards (No. 15 and No. 16). It includes extensive due diligence, risk disclosures, and verification of the equity change report content. This type of document is a formal report related to a significant change in shareholding or equity interests, which aligns with the category of Major Shareholding Notification (MRQ). The document is substantive and not merely an announcement or certification, and it is not an annual or interim financial report, nor a proxy or voting result announcement. Therefore, the best fitting classification is Major Shareholding Notification (MRQ).
2022-07-17 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.